Welcome to our dedicated page for NERVGEN PHARMA news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on NERVGEN PHARMA stock.
NervGen Pharma Corp (symbol: NGENF) is a clinical-stage biotech company focused on developing cutting-edge solutions for treating nervous system damage. Their lead drug candidate, NVG-291, is currently in a Phase 1b/2a clinical trial, targeting spinal cord injury as the initial indication. The company recently reported its financial and operational results, highlighting progress in recruitment for their clinical study and receiving Fast Track designation from the FDA. With a strong focus on innovative treatments and dedicated research efforts, NervGen is committed to enabling the nervous system to repair itself in cases of injury or disease.
NervGen Pharma Corp. (TSX-V: NGEN, OTCQX: NGENF) announced a peer-reviewed study showing that its drug NVG-291-R significantly improves motor and sensory functions in rodent models of severe ischemic stroke, even when treatment starts 7 days post-stroke. Currently, there are no FDA-approved treatments that repair stroke damage. NVG-291 is under a Phase 1 clinical trial, with plans for Phase 1b/2 trials targeting spinal cord injury, Alzheimer’s disease, and multiple sclerosis. This research indicates a potential breakthrough in stroke treatment.
FAQ
What is the current stock price of NERVGEN PHARMA (NGENF)?
What is the market cap of NERVGEN PHARMA (NGENF)?
What is NervGen Pharma Corp focused on?
What is NVG-291, and what is its current status?
What recent achievements has NervGen reported?
What sets NervGen apart in the biotech industry?
